You are here

Our science / Clinical Trials / Find a Trial / NCT00977561

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Back to Search Print Save as PDF Bookmark Trial

NCT00977561

Last updated on February 20, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Washington, District of Columbia, 20007-2197 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Small Cell Lung Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed diagnosis of extensive stage disease Small Cell Lung Cancer
(SCLC), with tumor biopsy sample required.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Total IGF-1 > or
= 120 ng/ml

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any prior systemic therapy for Small Cell Lung Cancer (SCLC)

- HbA1c > or = 5.7%

NCT00977561
Pfizer
Terminated
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Non-Small-Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Lung Neoplasms
Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
NCT00067548
All Genders
Lung Neoplasms, Non-small Cell Lung Carcinoma
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00094094
All Genders
18+
Years
Multiple Sites
Non-Small Cell Lung Carcinoma
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
NCT00174356
All Genders
18+
Years
Multiple Sites
Non Small Cell Lung Carcinoma
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
NCT00548093
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now